The influence of calcium mupirocin nasal ointment on the incidence of Staphylococcus aureus infections in haemodialysis patients.
Mupirocin was used in haemodialysis patients in an attempt to eradicate nasal carriage of Staphylococcus aureus and to prevent infection caused by this microorganism. The effectiveness of calcium mupirocin as a 2% nasal ointment OB2 (16 patients for 104 patient-months) was compared to that of placebo (18 patients for 147 patient-months) in a double-blind study. Mupirocin or placebo were applied in both anterior nares thrice daily for 2 weeks and subsequently three times weekly for a total of 9 months. During therapy, S. aureus was recovered from only 6% of the nasal cultures in the mupirocin group compared to 58% in the placebo group (P less than or equal to 0.01). Only one S. aureus infection was documented in the mupirocin group compared to six in the placebo group (P less than or equal to 0.05). The S. aureus strain causing the single infection in the mupirocin group was of a different phage type to that of the original nasal strain. In contrast, at least four of the six strains causing infection in the placebo group were of similar phage type to the original nasal strain. All S. aureus isolates remained mupirocin sensitive (MIC less than or equal to 1 mg/l). In conclusion, mupirocin nasal ointment was effective in eradicating nasal carriage of S. aureus and in preventing S. aureus infections in patients on haemodialysis.
Boelaert
J R
JR
Unit for Renal and Infectious Diseases, Algemeen Ziekenhuis St.-Jan, Brugge, Belgium.
De Smedt
R A
RA
De Baere
Y A
YA
Godard
C A
CA
Matthys
E G
EG
Schurgers
M L
ML
Daneels
R F
RF
Gordts
B Z
BZ
Van Landuyt
H W
HW
D000281:Administration, Intranasal; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002353:Carrier State; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005227:Fatty Acids / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016712:Mupirocin; D009666:Nose / Q000382:microbiology; D009824:Ointments; D011897:Random Allocation; D006435:Renal Dialysis / Q000009:adverse effects*; D013203:Staphylococcal Infections / Q000517:prevention & control*
D000900:Anti-Bacterial Agents; D005227:Fatty Acids; D009824:Ointments; D016712:Mupirocin